Allopurinol hypersensitivity can develop in 2% of cases (severe in 0.4%). If no alternative, oral desensitization is effective but it is associated with difficulties in monitoring and safety. A 65-yearsold Saudi male presented to allergy clinic at King Abdulaziz University Hospital as a case of type I hypersensitivity to Allopurinol. Phase I desensitization was conducted in the clinic over 4 hours by increasing doses of oral Allopurinol, starting from 0.01 mg up to 1 mg. Phase II desensitization was performed at home over 5 weeks with increasing doses from 1mg up to 100 mg/day (pharmaceutical dose). Daily e-mail messages were very helpful in patient monitoring by providing proper advices. Minor allergy symptoms, like itching and rash, resolved with oral antihistamines and maintaining the same dose until clear. To our knowledge, this is the first case report of using e-mail as an effective tool for monitoring successful oral drug desensitization.
INTRODUCTION
Allopurinol, an xanthine oxidase inhibitor, is a widely prescribed urate lowering agent in patients with hyperuricemia and gout [1] . Usually, it is well tolerated by nearly all patients, and the side effect is rare [2] . However, adverse reactions have been reported in about 10% of the patients, usually in the form of gastrointestinal and neurological effects [3] . Furthermore, hypersensitivity reactions can develop in 2 % of cases and may be severe in 0.4% [4, 5] . The onset of hypersensitivity ranged from one day to up-to two years after starting therapy, with an average of 47 days, which can impede its further uses [6] .
The mechanism of allopurinol hypersensitivity is not completely understood [7] . Literature reviews showed that there are at least three main patterns of hypersensitivity to allopurinol: 1) Non specific skin rash, 2) Type 1 immunoglobulin E (IgE) mediated hypersensitivity reaction (urticaria, angioedema, anaphylaxis), 3) Cell mediated hypersensitivity syndrome [8, 9] .
The diagnosis confirmation of clinically suspected IgE mediated drug allergy is mainly based on in vivo (skin tests) and/or in vitro IgE tests (specific serum IgE antibodies, or Basophil activation test). However, negative IgE tests do not have sufficient sensitivity to exclude hypersensitivity in the cases of highly suggestive history. Some standardized drug preparations may have a sensitivity of up to 70% in skin tests [10] . Unfortunately, these preparations are not commercially available for most drugs. Subsequently, drug allergy is mainly diagnosed by the constellation of exposure, timing, and clinical features including the pattern of organ manifestations [11, 12] .
In most cases with drug allergy, the treatment is usually based on the use of antihistamines and corticosteroids; avoidance of the component which caused the reaction, and switching to other alternatives [13] . However, when there are no other alternatives available in the market and therapy is mandatory with this drug, in this case the use of an oral desensitization procedure with gradually increasing doses may-be a good output [13] . Subsequently, the re-use of therapeutic doses can be obtained safely [14] .
The most intricate part in the desensitization procedure is the patient's need to a very close up monitoring for any side effect or allergic reaction which may need immediate attention. The aim of this study is to assess the effectiveness and safety of using electronic mail (e-Mail) as a modern way of communication for a secure 24 hours monitoring during the desensitization process in a case of allopurinol hypersensitivity to sense any side effect early, and to initiate urgent response when needed.
CASE HISTORY
This is a case of 65-year-old Saudi man with a known history of hyperuricemia for 4 years. Allopurinol therapy 100 mg, once daily (Zyloric®), was started as a treatment for hyperuricemia. Unfortunately, after three months of taking allopurinol, he developed two reactions in the form of an untolerated generalized pruritic urticarial erythematous rash. The second attack was associated with mild lips swelling which occurred immediately after taking the tablet. These reactions were relieved after stopping allopurinol therapy in few days with antihistamines, and he was not taking any other medication during that time. His family and social history was unremarkable.
As drug hypersensitivity was clinically suspected, allopurinol was stopped to control the allergic reactions, and oral antihistamine chlorpheniramine maleate B.P 4 mg (HISTOP®, SPIMACO) was prescribed. Furthermore, diet modification to reduce uric acid levels was advised. Additionally, the use of low-dose aspirin, diuretics, and other drugs that increase urat levels were also topped. In spite of these steps, the measurement of uric acid level was still high, and the patient continued to have recurrent joint pain, as well as several tophaceous swellings due to the uncontrolled hyperuricemia. He was referred by his rheumatologist to the allergy clinic for allopurinol desensitization since there was no alternative available in the market to control hyperuricemia.
At the allergy clinic at King Abdulaziz University Hospital (KAUH), private clinics in Jeddah; his clinical data was revaluated. The diagnosis of an IgE hypersensitivity to allopurinol was verified due to a clear correlation of typical symptoms immediately after exposure. Since there is no single standardized diagnostic test to confirm allopurinol hypersensitivity; it is mainly diagnosed by the constellation of exposure, timing, and clinical features including the pattern of organ manifestations [12, 15] .
Laboratory evaluation at KAUH showed normal electrolytes, renal, and liver functions, but with a high uric acid level at 593 umol/l (n = 155-428). Complete blood count was within normal, except that the eosinophil count was high, 5.9% (n = 1-3). Total serum IgE was within normal range, and specific IgE antibodies to common food and inhalant allergens were negative.
As there was a mandatory use of allopurinol for severe gout and no other alternatives were available to allopurinol, management in the allergy clinic at KAUH, private clinics were initiated with the use of allopurinol desensitization protocol as an acceptable and safe tool of drug allergy treatment [4] .
THE INTERVENTION
The desensitization procedure and its potential risks were discussed with the patient and his family, and then an informed verbal consent was obtained from the patient.
Oral desensitization was planned over two phases using gradually increasing doses of allopurinol. The chosen desensitization procedure, which was a modified one from several protocols reported in the literature, was used safely and successfully in outpatient settings [15] [16] [17] . The slow oral desensitization protocol to allopurinol was selected as the long-term efficacy and safety was confirmed [16] .
Allopurinol oral suspension was prepared at the pharmacy department at KAUH from allopurinol tablets 100 mg dissolved in universal vehicle 1,000 ml (methylcellulose solution1%, a simple syrup consist of sucrose powder in water for injection 500 ml), at a concentration of 20 mg per ml.
Phase I Desensitization took place at the allergy clinic at KAUH over 4 hours. Desensitization was initiated at 7:00 pm on Tuesday, 18th of May 2010 by using a very low oral dose of 0.01 mg at a concentration of 0.02 mg per ml diluted 3 times. The doses were increased gradually every 15 minutes and reached a dose of 1 mg (Table 1 ). All throughout the Phase I desensitization procedure, his vital signs were measured every 15 minutes and were within normal range.
The subsequent doses were taking at home in Phase II Desensitization starting from 1 mg to a target dosage of 100 mg of allopurinol/day. He was instructed to continue on the same dose for 3 days if any mild reactions developed, and to take oral antihistamine chlorpheniramine maleate B.P 4 mg (HISTOP®) as needed. He was advised to prolong the period with the previous tolerated dose during the appearance of allergic symptoms as shown in Table 2 . He was also prescribed a self injectable epinephrine (EpiPen®, Dey Pharma, L.P.) as an emergency treatment in case of any systemic reaction or anaphylaxis that might occur, and to seek emergency care immediately. Additionally, he was advised to follow dietary plan for gout to achieve an optimal control of blood uric acid. A close follow up utilizing e-Mails as a modern and fast way of communication was arranged and direct phone contacts were reserved for serious reaction [18] .
Allergic reactions appeared first as a mild itching around the neck and lower limbs after taking the allopurinol suspension dose of 0.04 mg which was recovered after single dose of oral. Another mild localized itching around the neck and lower limbs developed at dose 0.08 mg, and recovered after a single dose of oral antihistamine. Such allergic reactions re-occurred at home at doses of 1 mg, 30 mg, 60 mg and the last one at 80 mg, but all were very mild reactions that were relieved with a single dose of oral antihistamine at each time.
There was a close 24 hours monitoring throughout the desensitization procedure by e-Mails for reporting any side effects and to receive appropriate response. E-Mail was a very helpful tool as several advantages could be seen; a close 24 hour monitoring of the case, through which it was advice to the patient to repeat the same dose when reaction occurs, and to take antihistamine when required. Moreover, e-Mail creates a more close and strong relationship between the treating physician and the patient. As well as to improve patient compliance as medical support is always with him and relives his concern in a very short time. Finally, it involve patients in supervising and documenting their own health care, processes that may activate patients and contribute to an improved health [18] .
The total duration of Phase II desensitization process at home was 26 days as shown in Table 2 . When the allopurinol doses have reached 100 mg/day with no serious side effect, the dose was repeated for three days, then the patient was advised to take the tablets form of 100 mg. He was seen in a 
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follow-up visit after the end of Phase II desensitization. The blood uric acid level has fallen within normal ranges and the desensitization process was maintained at this dose.
Further follow up visits were arranged for any late reactions, and the final dose of allopurinol after successful desensitization was adjusted. Compliance with daily allopurinol intake was stressed in which the patient, as in any missed dose, may lead to loss of tolerance and the need to repeat the desensitization process from the start.
DISCUSSION
Although the prevalence of hypersensitivity to oral allopurinol has been reported to be very low (0.4 -2%), it still can take place, as occurred in this case report [4] . Therefore, health care workers must keep in mind the possibility of allopurinol allergy when initiating such therapy, especially in the elderly people. Physicians who prescribe allopurinol must be aware of anaphylaxis as the most serious complication even if its prevalence is rare [19] .
There are few readily available alternative urate-lowering medications for individuals with hyperuricemia who are intolerant to allopurinol, but are only available in limited number in the international markets. There are several compounds currently under study that may provide other urate lowering therapeutic options in patients intolerant to allopurinol. They include agents such as Febuxostat, a nonpurine xanthine oxidase inhibitor, and recombinant urate oxidase [20, 21] .
Desensitization to allopurinol poses potential risks, and is not recommended as a first-choice treatment for all patients with allergic reactions to the drug [5, 22] . The procedure is beneficial in selected patients who had allergic reactions to this medication and were other alternative was not available, or who cannot be treated with other urate-lowering drugs, particularly those with gout, tophaceous gout, and renal insufficiency.
Several allopurinol desensitization protocols have been developed for those individuals. Slow oral desensitization to Table 2 . Desensi za on Protocol: Phase II at home
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allopurinol is a safe and effective regimen [23] . In a retrospective evaluation of an oral desensitization regimen in 32 patients, it was successful in 78% of them [14] . Nevertheless, there are case reports of patients who failed the first desensitization attempt, but were successful on the second attempt [4, 20] .
Other modes of desensitization include successful intravenous administration of allopurinol which has been reported for a patient whom rapid desensitization to allopurinol was desired [24] .
Continued monitoring of patients, both during and following desensitization, is important as hypersensitivity to the drug may recur [4] . Electronic communications have been shown to be effective in facilitating communication among providers and patients, therefore, allowing greater continuity of care, plus in more timely interventions [25] . E-mail communication for close follow up can be a very helpful tool for a 24 hours monitoring of patients progress without the need to come to the clinic.
Our case had a successful first attempt of oral allopurinol desensitization. He was followed closely using a 24 hour e-Mail communication for any hypersensitivity reaction and direct phone calling line in case of emergency, in addition to the routine clinic visit. Apart from very mild urticarial rash that resolve with oral antihistamine, the desensitization protocol was completed successfully.
In conclusion, results from the present study confirms the efficacy and safety of slow oral desensitization to allopurinol, and advocates the e-Mail use as a practical and successful monitoring tool to restore tolerability to the drug. The desensitization procedure can be carried out in an outpatient setting under close medical supervision using 24 hours e-Mail communication after careful planning and detailed discussion of the desensitization protocol with the patient prior to initiating of therapy is essential. The new intervention in this case report is the use of e-Mail as a communication tool to have a close follow-up of the desensitization process and to allow rapid intervention when needed. To our knowledge, this is the first case report in literature applying e-Mail communication for a close 24 hours monitoring during the desensitization procedure.
PATIENT EDUCATION
Educate and inform the patient about the potential benefits, the risks of corticosteroid treatment, and to encourage the patient to participate in choosing the treatment plan. Emphasize the importance of healthy dietary habits, and ensure adequate calcium and vitamin D supplementation. Also to emphasize compliance with the long-term treatment plans and to follow-up care in order to prevent relapses, flares, and subsequent morbidity secondary to corticosteroid therapy. Basically, advise patients to immediately seek medical care if symptoms recur.
